ArticleScientific reports2025
The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interleukin-1α (IL-1α) in pancreatic ductal adenocarcinoma: implications for immunotherapy and molecular biomarkers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Immune-related factors are closely associated with tumor progression and responses to immunotherapy. A systematic analysis of the immunogenomic landscape and the identification of key immune-related genes (IRGs) can contribute to a better understanding of pancreatic cancer. To identify immune-related genetic prognostic characteristics (IRGPs) of pancreatic cancer, we first constructed an IRGP model containing multiple immune-related genes and determined the relative contributions of each gene using coefficients from the Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis. Subsequently, the prognostic value of the signature was validated through receiver operating characteristic (ROC) curve analysis and Kaplan-Meier survival analysis. Additionally, we explored the potential relationship between IRGPs and immune cell infiltration. Nine gene prognostic features were identified as the optimal IRGPs, which include six high-risk genes and three low-risk genes. Principal Component Analysis (PCA) demonstrated that this feature can effectively distinguish between high-risk and low-risk groups. The area under the curve (AUC) value indicated that IRGPs provide better prognostic clinical utility compared to existing TNM staging classifications. The median overall survival (OS) of high-risk patients was significantly shorter, and the infiltration levels of 24 immune cell types were lower. This study identified nine genes that have been identified as important prognostic biomarkers with immune-related characteristics for pancreatic cancer. Furthermore, we also explored the role of AIM2 in pancreatic cancer among the immune-related signature genes. AIM2 may influence the immune invasion and immunotherapy of pancreatic cancer by promoting the inflammatory environment of pancreatic cancer. AIM2 could be a new therapeutic target for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.